Parathyroid carcinoma is an extremely rare endocrine malignancy, accounting for an estimated 0,005% of all cancers and less than 1% of primary hyperparathyroidism cases. The majority of parathyroid cancer tumors are hormonally functional and hypersecrete parathyroid hormone which then increases serum calcium levels. Bone pain, pathologic fracture, pancreatitis, peptic ulcer, anemia and other organs damage are common complication of hypercalcemia. The primary treatment is surgical en block resection of a tumor, also the resection of local recurrence and metastatic lesions are recommended. Radiotherapy and chemotherapy shoved no evidence of effectiveness on parathyroid carcinoma. Fluid resuscitation, diuretics to promote calcium diuresis and calcium lowering drugs (bisphosphonate and calcimimetic) are the first line therapy for hypercalcemia. Denosumab, a monoclonal antibody that inhibits differentiation and stimulation of osteoclasts, bone resorption and thereby promotes reduction in serum calcium concentration is the effective treatment of hypercalcemia. The prognosis of parathyroid cancer is variable. Early identification, appropriate surgery, medical treatment for hypercalcemia and dissection of abnormal lymph nodes offer the best prognosis. The aim of this study is to present the series of patients with parathyroid carcinoma and compare our findings with those from the literature.